Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-17. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
=== US opposition === Senior Republicans as well as Democrats described Trump's tariff threats as bad for the United States, bad for business, and a strategic gift to Vladimir Putin and Xi Jinping. On the other hand, Trump said that Greenland was a US national security priority because he did not want Russia or China as neighbours, although Russia is already a neighbour of the United States; at their closest points, the American island of Little Diomede and the Russian island of Big Diomede in the Bering Strait are only 3.8 km (2.4 mi) away from each other. Senate minority leader Chuck Schumer announced that Democrats would introduce legislation to block any tariffs "before they do further damage to the American economy and our allies in Europe".
The technology of fragrances came with the invention of distillation, which allowed to be concentrated and sometimes even separated into individual components. The purification of cinnamaldehyde, the first single component fragrance, marked the beginning of the fragrance and flavor industries. Other single component fragrance compounds that were purified in the 19th century include benzaldehyde, methyl salicylate (oil of wintergreen), and vanillin. Somewhat in step with the synthetic dye industry, the fragrance and flavor industry was established. Many fragrance compounds were prepared synthetically. Spectroscopic methods coupled with various separation techniques allowed the identification of traces of aroma compounds (e.g. in wines, flower extracts, etc.). Tetramethyl acetyloctahydronaphthalenes have been described as "the most successful synthetic fragrance". The invention of gas chromatography was very important to the development of fragrances. Gas chromatography-olfactometry sometimes involving a human operator sniffing the GC effluent is particularly relevant to the analysis of fragrances. GC-O and related techniques have also been developed to characterize individual enantiomers of chiral aromatic compounds. Studies on synthetic musk reveal that the odors of some compounds are noticeably affected by deuteration. Various fragrant fruits are commercially cultivated to have appealing or intensified aromas.
As a consequence of altered kinase activity of a CK1δ S370A mutant, subsequently affected Wnt/β-catenin signal transduction resulted in development of an ectopic dorsal axis in Xenopus laevis embryos. Further residues targeted by site-specific phosphorylation are depicted in Figure 2. Mutation of identified target sites to the non-posphorylatable amino acid alanine leads to significant effects on catalytic parameters of CK1δ in most cases, at least in vitro. Evidence was also generated in cell culture-based analyses, which show reduced CK1-specific kinase activity after activation of cellular Chk1, and increased activity of CK1 after treatment of cells with the PKC-specific inhibitor Gö-6983 or the pan-CDK inhibitor dinaciclib. These findings indicate, that site-specific phosphorylation mediated by Chk1, PKCα, and CDKs actually results in reduced cellular CK1-specific kinase activity. However, robust in vivo phosphorylation data are missing in most cases and biological relevance and functional consequences of site-specific phosphorylation remains to be investigated for in vivo conditions. Moreover, phosphorylation target sites within the kinase domain have not been extensively characterized yet and are object to future research.
Naram-Sin was a son of Manishtushu. He was thus a nephew of King Rimush and grandson of Sargon and Tashlultum. Naram-Sin's aunt was the High Priestess Enheduanna. Most recensions of the Sumerian King List show him following Manishtushu but the Ur III version of the king list inverts the order of Rimush and Manishtushu. To be fully correct, rather than Naram-Sin or Naram-Suen "in Old Akkadian, the name in question should rather be reconstructed as Naram-Suyin (more precisely, /narām-tsuyin/) or Naram-Suʾin (/narām-tsuʾin/)".
Sources: en.wikipedia.org
In 2005, Neptune Resources NL, a mineral exploration company, applied for and was granted 35,000 km2 of exploration rights over the Kermadec Arc in New Zealand's Exclusive Economic Zone to explore for seafloor massive sulfide deposits, a potential new source of lead-zinc-copper sulfides formed from modern hydrothermal vent fields. The discovery of a vent in the Pacific Ocean offshore of Costa Rica, named the Medusa hydrothermal vent field (after the serpent-haired Medusa of Greek mythology), was announced in April 2007. The Ashadze hydrothermal field (13°N on the Mid-Atlantic Ridge, elevation -4200 m) was the deepest known high-temperature hydrothermal field until 2010, when a hydrothermal plume emanating from the Beebe site (18°33′N 81°43′W, elevation -5000 m) was detected by a group of scientists from NASA Jet Propulsion Laboratory and Woods Hole Oceanographic Institution. This site is located on the 110 km long, ultraslow spreading Mid-Cayman Rise within the Cayman Trough. In early 2013, the deepest known hydrothermal vents were discovered in the Caribbean Sea at a depth of almost 5,000 metres (16,000 ft). Oceanographers are studying the volcanoes and hydrothermal vents of the Juan de Fuca mid ocean ridge where tectonic plates are moving away from each other. Hydrothermal vents and other geothermal manifestations are currently being explored in the Bahía de Concepción, Baja California Sur, Mexico.
Second, Downstream-peptides are consistently positioned in a place that is consistent with a cis-regulatory role in regulating the downstream ORFs, although the biological role of the ORFs is unknown. Third, the pseudoknot structure has a moderate complexity that is typical of riboswitches. Finally, the observation of regulation of a downstream ORF by nitrogen availability also suggests a cis-regulatory role of the element. This hypothesis is supported by biochemical and genetic data. First, both Downstream-peptide RNAs and glnA RNAs selectively bind glutamine. Second, reporter gene analysis of the Downstream-peptide motif revealed that this RNA promotes reporter gene expression upon binding of glutamine and can therefore be considered an activating riboswitch. Possible candidates to be regulated by the Downstream-peptide motif are genes that frequently carry the Downstream-peptide motif in their 5′UTR and encode small, unknown proteins that contain DUF4278 and are putative regulators of glutamine synthetase. This hypothesis is supported by the finding that expression of the DUF4278-containing glutamine synthetase inhibitory factor IF17 encoding gene gifB was shown to be regulated by the structurally related glnA RNA motif. Downstream-peptide RNAs overlap a predicted non-coding RNA called yfr6 that is over 200 nucleotides in length, but it was proposed that only the upstream region (corresponding to the Downstream-peptide motif) functions as an RNA structure. A distinct predicted non-coding RNA called yfr14 overlaps both yfr6 and Downstream-peptide RNAs.
In Portugal, public prosecution is conducted by the Public Prosecution Service which is headed by the prosecutor general. The main police organisations of Portugal are the Guarda Nacional Republicana (National Republican Guard), the Polícia de Segurança Pública (Public Security Police), a civilian police force that works in urban areas; and the Polícia Judiciária (Judiciary Police), a senior criminal police body, under the authority of the Minister of Justice and endowed with administrative autonomy. Portugal has 49 correctional facilities run by the Directorate-General for Reintegration and Prison Services (DGRSP). The facilities are classified by security level, and by degree of management complexity, and often house inmates with different legal statuses, risk levels, and criminal trajectories within the same facilities. Despite following a reintegration-oriented penal model, Portugal retains high prison occupancy and an average sentence length of 31.3 months and one of the world's highest prison suicide rates representing around 30% of the 60 to 70 deaths occurring annually.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.